Silvio Inzucchi is an Endocrinology/Metabolic physician. OpenAlex indexes 753 publications with 84,136 citations (h-index 115). By OpenAlex citation count, this profile ranks in the top 1% of Endocrinology, Diabetes & Metabolism profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
789 Howard Ave
Dana Building - 3rd Floor
New Haven, CT 065191304
Telephone
203-737-1932Registry record last updated 21 Jul 2008.
Industry payments
20 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Boehringer Ingelheim RCV GmbH & Co KGProgram year20255 payments$27,405openpaymentsdata.cms.gov ↗
- Corcept TherapeuticsProgram year20256 payments
- Boehringer Ingelheim International GmbHProgram year20256 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Hormonal (systemic)
41.4%l-Thyroxine35.5%Levothyroxine Sodium83%Synthroid13%Levoxyl4%Part D<11 patientsThyroid Hormone Synthesis Inhibitor2.5%Methimazole100%Part D≥16 patients+ 2 more classes in this area
Metabolism & gastrointestinal
32.5%Corticosteroid11%Prednisone100%Part D≥47 patientsGLP-1 receptor agonist10.5%Ozempic73%Mounjaro14%Trulicity14%Part D<11 patients+ 8 more classes in this area
Cardiovascular
9.5%Statin4.7%Atorvastatin Calcium51%Rosuvastatin Calcium49%Part D≥14 patientsAldosterone antagonist (MRA)1.7%Spironolactone100%Part D<11 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 1997–2001 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
New England Journal of Medicine
2025 - Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
New England Journal of Medicine
2022 - Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the <scp>DELIVER</scp> trial
European Journal of Heart Failure
2021
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Yousef Saleh Khader
Jordan University of Science and Technology
Jens Juul Holst
University of Copenhagen
Victor Montori, MD
Mayo Clinic
Christos Mantzoros, MD
Harvard Medical School
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”